Literature DB >> 9356685

Development of an end-stage renal disease managed care demonstration.

B S Cooper1, P W Eggers, B M Edington.   

Abstract

At present, end-stage renal disease (ESRD) beneficiaries cannot enroll in health maintenance organizations (HMOs) or social health maintenance organizations (SHMOs), but HMO members who develop ESRD may remain enrolled, and the Health Care Financing Administration (HCFA) pays the HMO a state-specific, but otherwise unadjusted, capitation rate that is 95% of fee-for-service (FFS) costs. Thus, more than 6,000 ESRD beneficiaries were enrolled in HMOs in 1993, when Congress mandated an ESRD SHMO demonstration in which not only Medicare-covered services, but extra benefits were to be provided to Medicare beneficiaries, with the SHMO receiving a capitation rate based on 100% of FFS costs. The demonstration will test (1) the feasibility of year-round open enrollment of ESRD beneficiaries in HMOs; (2) a capitation system based on treatment status--dialysis, transplant, or functioning graft--and adjusted for age and whether diabetes was the cause of renal failure; (3) the effect of the additional benefits; and (4) whether managed care can improve ESRD quality outcomes. HCFA made demonstration awards in September 1996 to Kaiser-Permanente in Southern California; Health Options in Southern Florida; and Phoenix Healthcare in Central Tennessee. The sites are expected to have 1 year of planning and development before beginning the congressionally mandated 3 years of service delivery. There will be an independent evaluation.

Entities:  

Mesh:

Year:  1997        PMID: 9356685     DOI: 10.1016/s1073-4449(97)70022-0

Source DB:  PubMed          Journal:  Adv Ren Replace Ther        ISSN: 1073-4449


  4 in total

1.  Ongoing Lessons from the Comprehensive ESRD Care Program.

Authors:  Alan C Kinlaw; Abhijit V Kshirsagar
Journal:  Kidney360       Date:  2022-05-05

2.  Keys to Driving Implementation of the New Kidney Care Models.

Authors:  Abhijit V Kshirsagar; Daniel E Weiner; Mallika L Mendu; Frank Liu; Susie Q Lew; Terrence J O'Neil; Scott D Bieber; David L White; Jonathan Zimmerman; Sumit Mohan
Journal:  Clin J Am Soc Nephrol       Date:  2022-03-14       Impact factor: 10.614

3.  Risk-adjustment system for the Medicare capitated ESRD program.

Authors:  Jesse M Levy; John Robst; Melvin J Ingber
Journal:  Health Care Financ Rev       Date:  2006

4.  Evaluation of the ESRD managed care demonstration operations.

Authors:  Caitlin Carroll Oppenheimer; Jennifer R Shapiro; Nancy Beronja; Dawn M Dykstra; Daniel S Gaylin; Philip J Held; Robert J Rubin
Journal:  Health Care Financ Rev       Date:  2003
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.